All News
Cancer Survival with TNF Inhibitors (3.28.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read Article
Repetitive Transcranial Magnetic Stimulation in Fibromyalgia
A randomized, sham-controlled trial has shown that repetitive transcranial magnetic stimulation (rTMS) reduced pain in fibromyalgia for up to 8 weeks; while analgesic effects waned, functional improvements remained during extended maintenance at week 16.
Read Article
Cardiac-MSK Patients at Highest Risk for Falls and Death
d
EurekAlert!
A new study by researchers at Peking University and the Chinese PLA General Hospital has found that multimorbidity—living with multiple chronic diseases—is closely associated with worsening fall conditions and mortality among middle-aged and older adults in China.
Read Article
EUSTAR database study of 17,805 scleroderma (SSc) pts, 468 (2.6%) used HCQ with no effect on or improvement on HAQ-DI, or hand function scores when comparing HCQ users to non-HCQ users. https://t.co/Tu4tfG74pn https://t.co/Kckx3zTiJ4
Dr. John Cush RheumNow ( View Tweet)
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/0i5ZMJSxnp https://t.co/zeQ7QhmA0n
Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk
Dr. John Cush RheumNow ( View Tweet)
Full read review on inflammatory myositis (Patient or med student level knowlegdge) Epidemiology
Risk Factors
Prognosis
Sxs, Dx, Differential Dx
Treatment
Complications
Myositis Guidelines
https://t.co/s0LtHyYeuS https://t.co/lMEpMIotSP
Links:
Dr. John Cush RheumNow ( View Tweet)
Missed RheumNow Live but still want the great coverage? For the first time ever, https://t.co/4UQlqwujiR 2025 is Available On Demand!
✔️ STEP Talks from top rheumatologists
✔️ Lectures on the biggest clinical challenges
✔️ Speaker slides and handouts you’ll use
Non-CME, https://t.co/lns8EQBZjw
Links:
Dr. John Cush RheumNow ( View Tweet)
Worse Outcomes in HLA-B27+ JIA
Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study.
https://t.co/VEKqHvO1qw https://t.co/49y0JQL0Gr
Dr. John Cush RheumNow ( View Tweet)
Korea National Health Insurance Database review shows that risk of mortality in Behcets patients is 28% higher than gen. population; highest in 1st 12 mos (OR 2.66). Major causes were CA, CVD, GI (viscus rupture), respiratory, & infections. Higher in younger pts. https://t.co/BoBmpF08bx
Dr. John Cush RheumNow ( View Tweet)
If COVID was responsible for causing autoimmune Dz (AD), it is possible that Molecular mimicry was in play. Study shows 10nsequence homology between SARS-CoV-2 & AD epitopes; 2) similar MHC binding; 3) of high empirical immunogenicity. https://t.co/n2KK0UZq1J https://t.co/HF7wyDlSBF
Dr. John Cush RheumNow ( View Tweet)
MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/6NsMYocdEl
Dr. John Cush RheumNow ( View Tweet)
Machine learning model can predict RA progression from seroneg (SN) undiff. arthritis. KURAMA cohort -210 SN pts -- 57 (27%) progressed to RA. FNN model best w/ AUC 0.924 & sensitivity 81%. Validated in ANSWER cohort (140 pts; 32% became RA) AUC 0.77 sensitivity 78%. MMP-3 had https://t.co/2kiAU8r3B8
Dr. John Cush RheumNow ( View Tweet)
Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/sQMITpZbn3 https://t.co/up474pecNL
Dr. John Cush RheumNow ( View Tweet)
Treating chronic inflammatory diseases with JAK inhibitors
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since their approval, the https://t.co/MUHLUbK5Ml
Dr. John Cush RheumNow ( View Tweet)
Peripheral Nerve Blocks for Hip Fractures
JAMA reviews the use of peripheral nerve block with hip fractures as an effective pain management strategy that can be performed by credentialed clinicians outside of the operating room.
https://t.co/baeLWVxeUo https://t.co/ZBTVDT0jGR
Dr. John Cush RheumNow ( View Tweet)
A comprehensive examination of the pathogenesis and recent advancements in Familial Mediterranean Fever (FMF). This condition results from autosomal recessive mutations in the MEFV gene, which codes for Pyrin, a crucial component of the NLRP3 inflammasome. These genetic https://t.co/XNV89LW893
Dr. John Cush RheumNow ( View Tweet)
In 2021, the worldwide market for rheumatoid arthritis was valued at USD 22.77 billion and is projected to grow to USD 33.30 billion by 2030. https://t.co/HoUdQZfU8Q. https://t.co/Bcx9JMsavU
Links:
Dr. John Cush RheumNow ( View Tweet)
A study in mice shows that JAK inhibition In mice model of status epilepticus (SE) didnt prevent initial SE but when did effect chronic phase of Sz weeks after SE induction of SE, suppressing seizures, and epilepsy-associated histopathological alterations. Sz suppression lasted https://t.co/GMIPCtoc7x
Dr. John Cush RheumNow ( View Tweet)
ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting non-glycine citrulline motifs assoc. more strongly w/ HLA-SE; ACPA to glycine citrulline motifs assoc. w/ smoking and IgA ACPA
A&R
https://t.co/PmKv3dZLc4 https://t.co/NdPG4Orfj4
Links:
ACR_Journals ACR_Journals ( View Tweet)